Therapeutic Dual Inhibition of HER2 Pathway in Metastatic Colorectal Cancer

Speaker: Salvatore Siena

HER2 Amplification in metastatic colorectal cancer (mCRC) associates with resistance to anti-EGFR monoclonal antibodies. S. Siena elaborates results from HERACLES, the first precision medicine trial with positive results in mCRC. As predicted by xenografts, the combination of trastuzumab and lapatinib was remarkably active in standard therapy refractory mCRCs with HER2 Amplification.

Discussion Points

  • HER2 amplification as a driver of resistance to EGFR antibodies
  • Findings from patient-derived Xenograft models
  • Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients: The results from arm A of the HERACLES trial. (ASCO 3508)
  • Clinical interpretation of data